The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Apotex

Biotech Trends Update — IP Constituencies: Innovator-Generic Mixing Continues in Canada

As traditional pharma companies continue to diversify their revenue sources in the face of their pending patent cliffs, we have followed their entry into and expansion of their generics business lines. We have also noted activity in the reverse – generics companies developing novel products to build their margins and take advantage of their production capacity and expertise.

This week saw a Canadian example of the latter trend in Pharmascience’s purchase of Aegera for undisclosed terms. Pharmascience is a Montreal-based generics company and Aegera is a cancer-focused clinical stage company that has been backed by a raft of mostly Canadian venture capital outfits.

Canada’s domestic “generics” companies are now almost uniformly mixed generic / innovator businesses. Apotex carries out R&D through its ApoPharma subsidiary and has at least one novel product on the market. Valeant (nee Biovail) has a number of novel products in its pipeline as well. This should be particularly noteworthy in the innovation and economic development communities given recent decreases in Canadian R&D activity by global innovator pharma companies.

Monday Biotech Deal Review: May 16, 2011

Welcome to your Monday Biotech Deal Review for May 16, 2011. Angiotech has completed its second amended and restated plan of compromise or arrangement, cleaning up USD$250M in debt in respect of 7.75% senior subordinated notes, which are now cancelled, and has also resulted in the restructuring of $325M of existing floating rate notes through an exchange transaction.  There was also interesting licensing activity, notably involving Paladin Labs.  Lastly, Arch Biopartners announced their development achievement of a “bio-steel” material that is approximately 40% harder and 50% less corrosive than regular stainless steel.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought… after the jump

Canada’s Data Protection Regulations Upheld Against Court Challenge

Scale_of_justiceJPEGLast Friday* the Federal Court of Canada upheld the constitutional validity of Canada’s Data Protection Regulations, dismissing the applications of the Canadian Generic Pharmaceutical Association and Apotex Inc.

Canada’s data protection regime provides innovative drugs with:

  • a six-year data exclusivity period;
  • an eight-year market exclusivity period; and
  • an additional six-month period of market exclusivity in some cases for pediatric applications.

The Data Protection Regulations were enacted in 2006 to bring Canada into compliance with its TRIPS and NAFTA obligations.  Here’s today’s press release from Rx&D.

*The decision has not yet been posted. The citation will be 2009 FC 725.

Share Button

Monday Deal Review: April 20, 2009

A relatively quiet week for the deal review this week…

Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 126 other followers